Metraipolis › archive › dc_a852eee4a4cc

Real-world validation of ECOG performance status and neutrophil-to-lymphocyte ratio in second-line paclitaxel plus ramucirumab for advanced gastric cancer — Europe PMC PMID:41737601

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41737601
DOI
10.1515/biol-2025-1191
License (as archived)
solo-consultazione
Archived
2026-11-07T03:36:30.839Z
SHA-256 of the archived text
893b417ad76e955ecb716fa882f0a9fd681d0e905d4c3823118b8bd8cce8da67
Stable URL of this page
https://metraipolis.com/documento/dc_a852eee4a4cc

How to cite

Real-world validation of ECOG performance status and neutrophil-to-lymphocyte ratio in second-line paclitaxel plus ramucirumab for advanced gastric cancer — Europe PMC PMID:41737601 — Europe PMC (en), https://europepmc.org/article/MED/41737601 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a852eee4a4cc (Metraipolis archive dc_a852eee4a4cc, sha256 893b417ad76e955ecb716fa882f0a9fd681d0e905d4c3823118b8bd8cce8da67)
BibTeX
@misc{dca852eee4a4cc,
  title = {Real-world validation of ECOG performance status and neutrophil-to-lymphocyte ratio in second-line paclitaxel plus ramucirumab for advanced gastric cancer — Europe PMC PMID:41737601},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41737601},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a852eee4a4cc; sha256 893b417ad76e955ecb716fa882f0a9fd681d0e905d4c3823118b8bd8cce8da67},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41737601. Agents can read the archived copy with the MCP tool read_document.